直 Japanese PDF Font
  • Our Professionals
  • Our Work
  • Our Insights
  • Offices
  • Firm
  • Careers
Finnegan
  • Articles & Books
    • Ad Law Buzz Blog
    • At the PTAB Blog
    • European IP Blog
    • Federal Circuit IP Blog
    • INCONTESTABLE® Blog
    • Prosecution First Blog
  • Events & Webinars
  • IP Updates
  • Podcasts
    • AI + Finnegan
    • AI + Copyright
    • AI + Patent
    • AI + Privacy
    • AI + Trade Secrets
    • AI + Trademark
  • Unified Patent Court (UPC) Hub

Prosecution First Blog

USPTO Revised Patent Fees, Oh My!

November 20, 2017

Authored and Edited by Adriana L. Burgy; Charles E. Van Horn

On November 14, 2017, the USPTO issued and published the final rule, “Setting and Adjusting Patent Fees during Fiscal Year 2017.”  The final rule set or adjusted certain patent fees, as provided by the Leahy-Smith America Invents Act (AIA).  This rulemaking is the second iteration of patent fee rulemaking by the USPTO under AIA; the first was January 2013. This rule is effective on January 16, 2018, for patent fees paid on or after January 16, 2018. 

The USPTO published a table summarizing the new or adjusted fees, which can be found here.  Below summarizes the notable changes in fees.

Fee

Current Large
Entity Fee Rate

Final Rule Large
Entity Fee Rate

Percentage Change

Utility Patent Application Fees

Utility Filing Fee

$280

$300

7%

Utility Search Fee

$600

$660

10%

Utility Examination Fee

$720

$760

6%

Utility Issue Fee

Utility Issue Fee

$960

$1000

4%

Provisional Application Filing

Provisional Application Filing Fee

$260

$280

8%

Design Patent Application Fees

Design Filing Fee

$180

$200

11%

Design Search Fee

$120

$160

33%

Design Examination Fee

$460

$600

30%

Design Issue Fee

Design Issue Fee

$560

$700

25%

Plant Patent Application Filing Fees

Plant Filing Fee

$180

$200

11%

Plant Search Fee

$380

$420

11%

Plant Examination Fee

$580

$620

7%

Plant Issue Fee

Plant Issue Fee

$760

$800

5%

Excess Claim Fees

Each Independent Claim in Excess of Three

$420

$460

10%

Each Claim in Excess of 20

$80

$100

25%

Multiple Dependent Claims

$780

%820

5%

Information Disclosure Statement (IDS)

Submission of an IDS after First Action on the Merits, before Notice of Allowance

$180

$240

33%

Request for Continued Examination (RCE)

RCE - 1st Request

$1,200

$1,300

8%

RCE - 2nd and Subsequent Request

$1,700

$1,900

12%

Appeal Fees

Notice of Appeal

$800

$800

no change

Forwarding an Appeal Brief in an Application or Ex Parte Reexamination Proceeding to the Board

$2,000

$2,240

12%

NEW Patent Fees

Ex Parte Reexamination (§ 1.510(a)) Streamlined

- -

$6,000

(non-streamlined remains at $12,000)

- -

Hague International Design Application

- -

$120

- -

Submission of sequence listing of 300 MB to 800 MB

- -

$1,000

- -

Submission of sequence listings of more than 800 MB

- -

$10,000

- -

Late Filing of Sequence Listing

- -

$300

- -

 

Tags

America Invents Act (AIA), United States Patent and Trademark Office (USPTO)

Related Practices

Patent Drafting and Prosecution

Contacts

Adriana L. Burgy
Partner
Washington, DC
+1 202 408 4345
Email

Copyright © 2017 Finnegan, Henderson, Farabow, Garrett & Dunner, LLP. 


DISCLAIMER: Although we wish to hear from you, information exchanged in this blog cannot and does not create an attorney-client relationship. Please do not post any information that you consider to be personal or confidential. If you wish for Finnegan, Henderson, Farabow, Garrett & Dunner, LLP to consider representing you, in order to establish an attorney-client relationship you must first enter a written representation agreement with Finnegan. Contact us for additional information. One of our lawyers will be happy to discuss the possibility of representation with you. Additional disclaimer information.

Related Insights

Conference

7th International Conference on Biofuels and Bioenergy

June 25-26, 2026

Edinburgh

Conference

IPBC Global 2026

June 15-17, 2026

San Diego

Conference

17th Summit on Biosimilars & Innovator Biologics

June 2-3, 2026

New York

At the PTAB Blog

Discretion All the Way Down: USPTO Uses a Discretionary IPR Denial to Justify a    
§ 325(d) EPR Denial

May 28, 2026

At the PTAB Blog

IPR and PGR Statistics for Final Written Decisions Issued in March and April 2026

May 26, 2026

At the PTAB Blog

Before the Holding, the Message: Director Squires Uses Magnolia Medical to Outline PTAB Discretionary Denial Policy Changes

May 20, 2026

Virtual Seminar

Patent "Basics" Seminar

May 19, 2026

Virtual

Conference

19th Annual Forum on Pharma & Biotech Patent Litigation in Europe

May 19-20, 2026

Amsterdam

Webinar

Changes at the PTAB from Settled Expectations to Real Parties in Interest to Director Involvement

May 18, 2026

Webinar

Due to international data regulations, we’ve updated our privacy policy. Click here to read our privacy policy in full.

  • Privacy
  • Disclaimer
  • Legal Notices
  • Fraud Alert
  • EEO Statement
  • Cookies
  • Contact Us

© 2026 Finnegan, Henderson, Farabow, Garrett & Dunner, LLP